β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells
Authors
Keywords
-
Journal
PLoS One
Volume 10, Issue 2, Pages e0117097
Publisher
Public Library of Science (PLoS)
Online
2015-02-07
DOI
10.1371/journal.pone.0117097
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Triple-Negative Breast Cancer: Clinical and Histological Correlations
- (2017) Zeinab Elsawaf et al. Breast Care
- APC/β-catenin-rich complexes at membrane protrusions regulate mammary tumor cell migration and mesenchymal morphology
- (2013) Matthew A Odenwald et al. BMC CANCER
- Genomic Profiling in Luminal Breast Cancer
- (2013) Oleg Gluz et al. Breast Care
- Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies
- (2013) Valentina Guarneri et al. DRUGS
- WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer
- (2013) Peter Wend et al. EMBO Molecular Medicine
- Adjuvant treatments for triple-negative breast cancers
- (2012) H. Joensuu et al. ANNALS OF ONCOLOGY
- Neoadjuvant treatments for triple-negative breast cancer (TNBC)
- (2012) G. von Minckwitz et al. ANNALS OF ONCOLOGY
- Wnt/β-Catenin Signaling and Disease
- (2012) Hans Clevers et al. CELL
- β-Catenin signaling dosage dictates tissue-specific tumor predisposition in Apc-driven cancer
- (2012) E R M Bakker et al. ONCOGENE
- Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity
- (2012) Z.-Q. Wu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The wnt/β-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer
- (2011) Taj D. King et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Apc Mutation Enhances PyMT-Induced Mammary Tumorigenesis
- (2011) Jenifer R. Prosperi et al. PLoS One
- Wnt/β-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome
- (2010) Andrey I. Khramtsov et al. AMERICAN JOURNAL OF PATHOLOGY
- Specific Killing of Rb Mutant Cancer Cells by Inactivating TSC2
- (2010) Binghui Li et al. CANCER CELL
- Cytoplasmic Localization of -Catenin is a Marker of Poor Outcome in Breast Cancer Patients
- (2010) E. Lopez-Knowles et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells?
- (2010) F. Takahashi-Yanaga et al. CLINICAL CANCER RESEARCH
- A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
- (2010) Jenifer R. Prosperi et al. CURRENT DRUG TARGETS
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation
- (2010) Felipe C Geyer et al. MODERN PATHOLOGY
- Wnt activity defines colon cancer stem cells and is regulated by the microenvironment
- (2010) Louis Vermeulen et al. NATURE CELL BIOLOGY
- Triple-negative breast cancer: disease entity or title of convenience?
- (2010) Lisa Carey et al. Nature Reviews Clinical Oncology
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors
- (2009) Jinhua Xu et al. BREAST CANCER RESEARCH AND TREATMENT
- A Novel Lung Metastasis Signature Links Wnt Signaling with Cancer Cell Self-Renewal and Epithelial-Mesenchymal Transition in Basal-like Breast Cancer
- (2009) Theresa A. DiMeo et al. CANCER RESEARCH
- Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling
- (2008) Ilaria Malanchi et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now